Disorders of Ventilation¶
Chapter 307 | Part 7: Disorders of the Respiratory System
KEY CLINICAL POINTS¶
- Hypoventilation is characterized by alveolar hypoventilation leading to hypercapnia (Paco2 ≥ 45 mmHg) and respiratory acidosis.
- Obesity hypoventilation syndrome (OHS) is a major cause of chronic hypoventilation, with prevalence estimated at 0.4% of U.S. adults.
- Noninvasive positive pressure ventilation (NIPPV) is the cornerstone of treatment for chronic hypoventilation and OHS.
1. DEFINITION & OVERVIEW¶
Hypoventilation refers to inadequate alveolar ventilation, leading to elevated arterial CO2 (Paco2) and respiratory acidosis. Hypercapnia results from imbalance between CO2 production and elimination. Alveolar hypoventilation occurs when minute ventilation fails to maintain Paco2 within the normal range (37–43 mmHg).
Table 307-1: Signs and Symptoms of Hypoventilation¶
| Signs and Symptoms | Description |
|---|---|
| Dyspnea during activities of daily living | Shortness of breath with exertion |
| Orthopnea | Difficulty breathing when lying flat |
| Daytime hypersomnolence | Excessive daytime sleepiness |
| Early morning headaches | Result of chronic CO2 retention |
| Paradoxical breathing | Abdomen moves inward during inspiration |
1.1 Alveolar Hypoventilation¶
Defined as Paco2 ≥ 45 mmHg at sea level. Results from reduced minute ventilation, increased dead space, or both. Chronic hypercapnia leads to compensatory bicarbonate retention and respiratory acidosis.
1.2 Hypercapnia and Respiratory Acidosis¶
Persistent elevation of Paco2 >45 mmHg causes respiratory acidosis. Compensatory mechanisms include increased bicarbonate levels and renal excretion of HCO3 − . Severe hypercapnia may lead to pulmonary hypertension and right heart failure.
2. EPIDEMIOLOGY¶
Obesity hypoventilation syndrome (OHS) is increasingly prevalent due to the global obesity epidemic. Estimated prevalence: 0.4% of U.S. adults (1 in 263). Risk factors include BMI ≥ 30 kg/m², severe obesity (BMI >40), and obstructive sleep apnea (OSA).
2.1 Obesity Hypoventilation Syndrome¶
Most common cause of chronic hypoventilation. Prevalence rises with BMI. Severe OSA (AHI >30 events/h) and BMI >40 are significant risk factors.
2.2 Neuromuscular Disorders¶
Amyotrophic lateral sclerosis (ALS), muscular dystrophy, and myasthenia gravis contribute to hypoventilation through respiratory muscle weakness. Early symptoms include reduced respiratory drive and paradoxical breathing.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Hypoventilation arises from imbalances between CO2 production and elimination. Key mechanisms include: 1) Reduced respiratory drive (central hypoventilation), 2) Increased ventilatory load (obesity, chest wall disease), 3) Impaired respiratory muscle strength (neuromuscular disease), 4) Obstructive sleep apnea (OSA).
3.1 Central Hypoventilation¶
Caused by brainstem dysfunction (e.g., stroke, tumors, PHOX2b mutations). Patients lack ventilatory response to hypercapnia/hypoxia. Congenital central hypoventilation syndrome (CCHS) is a genetic disorder linked to PHOX2b mutations.
3.2 Obstructive Hypoventilation¶
Results from airway obstruction (OSA) or chest wall abnormalities. Obesity increases ventilatory load, leading to CO2 retention. Ventilation-perfusion mismatch and reduced diaphragmatic efficiency exacerbate hypoventilation.
4. CLINICAL FEATURES¶
Symptoms vary by etiology. Common manifestations include dyspnea, orthopnea, daytime hypersomnolence, and paradoxical breathing. Chronic hypercapnia may cause secondary erythrocytosis and pulmonary hypertension.
4.1 Obstructive Sleep Apnea (OSA)¶
Patients present with snoring, daytime sleepiness, and nocturnal hypoxemia. Severe OSA (AHI >30) is strongly associated with OHS.
4.2 Neuromuscular Disorders¶
Progressive muscle weakness leads to respiratory insufficiency. Early signs include reduced maximal inspiratory/expiratory pressures and decreased vital capacity.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish between central, obstructive, and mixed hypoventilation. Consider COPD, neuromuscular disease, and OHS. Key differentiators include nocturnal hypercapnia, sleep study findings, and response to CPAP/NIPPV.
5.1 Central vs. Obstructive Hypoventilation¶
Central hypoventilation lacks obstructive features (e.g., snoring, stridor). Obstructive hypoventilation is associated with OSA and airway obstruction.
5.2 Chronic vs. Acute Hypoventilation¶
Chronic hypoventilation presents with gradual hypercapnia and compensatory bicarbonate retention. Acute exacerbations may show rapid CO2 retention and metabolic acidosis.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires arterial blood gas (ABG) analysis (Paco2 ≥ 45 mmHg). Polysomnography confirms OSA. Pulmonary function tests (PFTs) assess restrictive or obstructive lung disease. Serum bicarbonate levels ≥ 27 mmol/L suggest chronic hypoventilation.
Table 307-2: Diagnostic Criteria for Hypoventilation¶
| Criteria | Description |
|---|---|
| Paco2 ‡45 mmHg | Arterial blood gas confirmation |
| Serum bicarbonate ‡27 mmol/L | Suggests chronic hypoventilation |
| Nocturnal hypercapnia | Confirmed by polysomnography |
| BMI ‡30 kg/m² | Screen for OHS |
| MIP <60 cmH2O | Respiratory muscle weakness |
6.1 Diagnostic Algorithm¶
Step 1: Detailed history (medications, OSA, obesity). Step 2: Pulmonary function testing, chest imaging. Step 3: Measure MIP/MEP. Step 4: BMI ≥ 30 kg/m². Step 5: PSG for OSA. Step 6: CNS imaging for central causes.
6.2 Laboratory Tests¶
Arterial blood gas analysis (Paco2, pH, HCO3 − ). Serum bicarbonate levels ≥ 27 mmol/L confirm chronic hypoventilation. Venous blood gas may show elevated Pco2 (normal Paco2 + 5–7 mmHg).
7. MANAGEMENT & TREATMENT¶
NIPPV (BiPAP ST or volume-assured pressure support) is the primary treatment. Weight loss, CPAP, and addressing underlying causes (e.g., OSA, neuromuscular disease) are critical. Phrenic nerve pacing may be used in select cases.
Table 307-3: NIPPV Settings for Hypoventilation¶
| Parameter | Target Range |
|---|---|
| Inspiratory Pressure | 24–28 cmH2O |
| Backup Rate | 4–12 bpm |
| Tidal Volume | 6–8 mL/kg |
| Minute Ventilation | Maintain Paco2 <48 mmHg |
| Oxygen Concentration | Avoid >28% to prevent CO2 retention |
7.1 Noninvasive Ventilation¶
BiPAP ST (inspiratory pressure 24–28 cmH2O, backup rate 4–12 bpm) is preferred. NIPPV improves daytime hypercapnia, prolongs survival, and enhances quality of life in OHS and COPD.
7.2 Pharmacologic Therapy¶
Acetazolamide and medroxyprogesterone may stimulate respiration but are not first-line. Oxygen supplementation must be cautious to avoid worsening hypercapnia.
8. PROGNOSIS & COMPLICATIONS¶
Chronic hypercapnia leads to pulmonary hypertension, right ventricular hypertrophy, and cor pulmonale. OHS patients with severe OSA have higher mortality. Early intervention with NIPPV improves outcomes.
8.1 Complications of Hypoventilation¶
Pulmonary hypertension, right heart failure, secondary erythrocytosis, and respiratory infections. Severe hypercapnia may cause encephalopathy and cardiac arrhythmias.
8.2 Prognostic Factors¶
Early initiation of NIPPV, absence of comorbidities, and successful weight loss improve prognosis. Patients with CCHS require lifelong ventilatory support.
9. SPECIAL CONSIDERATIONS¶
Obesity hypoventilation syndrome (OHS) requires weight management and CPAP/NIPPV. Neuromuscular diseases necessitate respiratory muscle assessment and pacing. Pregnancy may worsen hypoventilation due to diaphragmatic compression.
9.1 Obesity Hypoventilation Syndrome¶
BMI ≥ 30 kg/m² with chronic daytime hypercapnia. Weight loss (20–25% of body weight) may normalize Paco2, but bariatric surgery is often required.
9.2 Neuromuscular Disorders¶
ALS and muscular dystrophy patients require early ventilatory support. Phrenic nerve pacing may improve quality of life in selected cases.
10. KEY POINTS & CLINICAL PEARLS¶
- Hypoventilation is defined as Paco2 ≥ 45 mmHg with respiratory acidosis.
- NIPPV is the first-line treatment for OHS and chronic hypoventilation.
- Obesity is the leading cause of chronic hypoventilation.
- Polysomnography is essential for diagnosing OSA.
- Acetazolamide may be used cautiously in chronic hypercapnia.